The University of Southampton
University of Southampton Institutional Repository

Genotype at the Sil-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis

Genotype at the Sil-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis
Genotype at the Sil-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis
Objectives

To investigate the association between genotype at the soluble interleukin 6 receptor (sIL-6R) A358C single nucleotide polymorphism (SNP, rs8192284), previously reported to correlate with soluble receptor levels, and response to anti-TNF therapy in subjects with RA.

Methods

In a large cohort of Caucasian RA patients treated with anti-TNF medications (total, n = 1050; etanercept, n = 455; infliximab, n = 450; and adalimumab, n = 142), the sIL-6R A358C polymorphism was genotyped using a Taqman 5'-allelic discrimination assay. Linear regression analysis adjusted for baseline 28 joint disease activity score (DAS28), baseline HAQ score, gender and use of concurrent DMARDs was used to assess the association of genotype at this polymorphism with response to anti-TNF therapy, defined by change in DAS28 after 6 months of treatment. Analyses were performed in the entire cohort, and also stratified by an anti-TNF agent. Additional analysis according to the EULAR response criteria was also performed, with the chi-squared test used to compare genotype groups.

Results

No association between genotype at sIL-6R A358C and response to anti-TNF treatment was detected either in the cohort as a whole or after stratification by anti-TNF agent, in either the linear regression analysis or with response segregated according to EULAR criteria.

Conclusions

This study shows that genotype at the functional sIL-6R A358C SNP is not associated with response to anti-TNF treatment in patients with RA.
infliximab, etanercept, adalimumab, anti-TNF, rheumatoid, IL-6 receptor, pharmacogenetics, biomarkers
1462-0324
43-47
Hassan, Batool
be986483-e870-4ef6-9785-edf29eb73fc0
Maxwell, James R.
15a16cd5-2499-42a9-a37d-56dd76ee908b
Hyrich, Kimme L.
bf2bc52a-6d8a-4ca3-9266-8e471155fad9
Barton, Anne
70cfdc4a-5e46-4708-a283-ce3484d16fa4
Worthington, Jane
9dfac193-b4a7-4898-b794-88c7a98acd5a
Issacs, John D.
4b9103b3-0b52-4997-b378-451e0577f8c9
Morgan, Ann W.
385b8e0c-1f40-4afb-80d4-ab8dc781a0ae
Wilson, Anthony G.
674d2ac8-e0d0-4f1e-a48a-2ad2166d62ac
Hassan, Batool
be986483-e870-4ef6-9785-edf29eb73fc0
Maxwell, James R.
15a16cd5-2499-42a9-a37d-56dd76ee908b
Hyrich, Kimme L.
bf2bc52a-6d8a-4ca3-9266-8e471155fad9
Barton, Anne
70cfdc4a-5e46-4708-a283-ce3484d16fa4
Worthington, Jane
9dfac193-b4a7-4898-b794-88c7a98acd5a
Issacs, John D.
4b9103b3-0b52-4997-b378-451e0577f8c9
Morgan, Ann W.
385b8e0c-1f40-4afb-80d4-ab8dc781a0ae
Wilson, Anthony G.
674d2ac8-e0d0-4f1e-a48a-2ad2166d62ac

Hassan, Batool, Maxwell, James R., Hyrich, Kimme L., Barton, Anne, Worthington, Jane, Issacs, John D., Morgan, Ann W. and Wilson, Anthony G. (2009) Genotype at the Sil-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis. Rheumatology, 49, 43-47. (doi:10.1093/rheumatology/kep372).

Record type: Article

Abstract

Objectives

To investigate the association between genotype at the soluble interleukin 6 receptor (sIL-6R) A358C single nucleotide polymorphism (SNP, rs8192284), previously reported to correlate with soluble receptor levels, and response to anti-TNF therapy in subjects with RA.

Methods

In a large cohort of Caucasian RA patients treated with anti-TNF medications (total, n = 1050; etanercept, n = 455; infliximab, n = 450; and adalimumab, n = 142), the sIL-6R A358C polymorphism was genotyped using a Taqman 5'-allelic discrimination assay. Linear regression analysis adjusted for baseline 28 joint disease activity score (DAS28), baseline HAQ score, gender and use of concurrent DMARDs was used to assess the association of genotype at this polymorphism with response to anti-TNF therapy, defined by change in DAS28 after 6 months of treatment. Analyses were performed in the entire cohort, and also stratified by an anti-TNF agent. Additional analysis according to the EULAR response criteria was also performed, with the chi-squared test used to compare genotype groups.

Results

No association between genotype at sIL-6R A358C and response to anti-TNF treatment was detected either in the cohort as a whole or after stratification by anti-TNF agent, in either the linear regression analysis or with response segregated according to EULAR criteria.

Conclusions

This study shows that genotype at the functional sIL-6R A358C SNP is not associated with response to anti-TNF treatment in patients with RA.

This record has no associated files available for download.

More information

Published date: 19 November 2009
Keywords: infliximab, etanercept, adalimumab, anti-TNF, rheumatoid, IL-6 receptor, pharmacogenetics, biomarkers

Identifiers

Local EPrints ID: 150219
URI: http://eprints.soton.ac.uk/id/eprint/150219
ISSN: 1462-0324
PURE UUID: 37b0d65e-85dc-4457-99df-64800fb90e1d

Catalogue record

Date deposited: 04 May 2010 14:53
Last modified: 14 Mar 2024 01:12

Export record

Altmetrics

Contributors

Author: Batool Hassan
Author: James R. Maxwell
Author: Kimme L. Hyrich
Author: Anne Barton
Author: Jane Worthington
Author: John D. Issacs
Author: Ann W. Morgan
Author: Anthony G. Wilson

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×